FDA Approves Dupixent® for Chronic Rhinosinusitis With Nasal Polyps
The U.S. Food and Drug Administration today approved Dupixent (dupilumab) to treat adults with nasal polyps (growths on the inner lining of the sinuses) accompanied by chronic rhinosinusitis (prolonged inflammation of the sinuses and nasal cavity). This is the first treatment approved for inadequately controlled chronic rhinosinusis with nasal polyps… Lesen Sie weiter auf: FDA [...] .../Auszug
